August Troendle Net Worth

The estimated Net Worth of August J. Troendle is at least $1.36 Billion dollars as of 24 May 2024. Mr. Troendle owns over 9,682 units of Medpace Inc stock worth over $219,028,258 and over the last 10 years he sold MEDP stock worth over $1,128,974,831. In addition, he makes $7,712,840 as Chairman of the Board, President, and Chief Executive Officer at Medpace Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Troendle MEDP stock SEC Form 4 insiders trading

August has made over 125 trades of the Medpace Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 9,682 units of MEDP stock worth $3,828,069 on 24 May 2024.

The largest trade he's ever made was buying 869,565 units of Medpace Inc stock on 16 August 2016 worth over $19,999,995. On average, August trades about 61,098 units every 23 days since 2014. As of 24 May 2024 he still owns at least 654,656 units of Medpace Inc stock.

You can see the complete history of Mr. Troendle stock trades at the bottom of the page.

August Troendle biography

DR. August J. Troendle M.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company since he founded the Company in July 1992. Before founding Medpace, Mr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz (Novartis), where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987, Mr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Mr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018, as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Troendle received his Medical Degree from the University of Maryland, School of Medicine.

What is the salary of August Troendle?

As the Chairman of the Board, President, and Chief Executive Officer of Medpace Inc, the total compensation of August Troendle at Medpace Inc is $7,712,840. There are no executives at Medpace Inc getting paid more.

How old is August Troendle?

August Troendle is 63, he's been the Chairman of the Board, President, and Chief Executive Officer of Medpace Inc since . There are 3 older and 11 younger executives at Medpace Inc. The oldest executive at Medpace Holdings Inc is Fred Davenport, 68, who is the Lead Independent Director.

What's August Troendle's mailing address?

August's mailing address filed with the SEC is C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI, OH, 45227.

Insiders trading at Medpace Inc

Over the last 8 years, insiders at Medpace Inc have traded over $3,140,136,825 worth of Medpace Inc stock and bought 2,899,276 units worth $330,034,155 . The most active insiders traders include Limited Partnership Medpace..., August J. Troendle, and Investors, Llc Medpace. On average, Medpace Inc executives and independent directors trade stock every 9 days with the average trade being worth of $40,224,347. The most recent stock trade was executed by Robert O. Kraft on 22 August 2024, trading 8,127 units of MEDP stock currently worth $346,373.

What does Medpace Inc do?

a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.

Complete history of Mr. Troendle stock trades at Coherus Biosciences Inc and Medpace Inc

Medpace Inc executives and stock owners

Medpace Inc executives and other stock owners filed with the SEC include:

• August Troendle,
  Chairman of the Board, President, Chief Executive Officer
• Susan Burwig,
  Executive Vice President - Operations
• Jesse Geiger,
  Chief Financial Officer, Chief Operating Officer - Laboratory Operations
• Stephen Ewald,
  General Counsel, Corporate Secretary
• Dr. August James Troendle M.D.,
  Chairman & CEO
• Susan E. Burwig,
  Exec. VP of Operations
• Jesse J. Geiger BBA, CPA,
  Pres
• Stephen P. Ewald,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Brian Carley,
  Independent Director
• Robert Kraft,
  Independent Director
• Fred Davenport,
  Lead Independent Director
• Cornelius McCarthy,
  Independent Director
• Ashley Keating,
  Independent Director
• Thomas King,
  Independent Director
• Brandon Ebken,
  Chief Information Officer
• John T. Wynne,
  Sr. VP of Commercial Operations & Clinical Pharmacology Unit
• Daniel O'Leary,
  Sr. VP of Medical Department
• Weimin Gai MS,
  Sr. VP of Biometrics
• Todd Meyers,
  VP of Bus. Devel. & Marketing
• Lauren Morris,
  Associate Director of Investors Relations
• Kevin M. Brady,
  CFO & Treasurer
• Penelope J Bucknell,
  VP, Human Resources
• Bruce Brown,
  Director
• Cinven Fund (No. 1) Limited...,
  
• Limited Partnership Medpace...,
  
• Dani S. Zander,
  Director
• Investors, Llc Medpace,
  10% owner
• Tom C King,
  Director
• Kevin M. Brady,
  CFO & Treasurer